武汉原生原代生物医药科技有限公司品牌商

5

手机商铺

qrcode
商家活跃:
产品热度:
  • NaN
  • 0.5
  • 0.5
  • 2.5
  • 2.5
品牌商

武汉原生原代生物医药科技有限公司

入驻年限:5

  • 联系人:

    李经理

  • 所在地区:

    湖北 武汉市

  • 业务范围:

    试剂、技术服务、细胞库 / 细胞培养

  • 经营模式:

    生产厂商

在线沟通
推荐产品

大鼠软骨细胞

品牌:PriCells(原生原代)

¥3580

咨询

小鼠主动脉平滑肌细胞

品牌:PriCells(原生原代)

¥3580

咨询

人软骨细胞

品牌:PriCells(原生原代)

¥7580

咨询

兔T淋巴细胞

品牌:PriCells(原生原代)

¥5180

咨询

兔B淋巴细胞

品牌:PriCells(原生原代)

¥5180

咨询
查看全部产品

公司新闻/正文

贺华中科技大学同济医学院附属同济医院应用PriCells产品/技术服务发表文章

358 人阅读发布时间:2015-04-03 09:50

贺华中科技大学同济医学院附属同济医院应用PriCells产品/技术服务发表文章
 
 
Stroke. 2014 Feb;45(2):383-8. doi: 10.1161/STROKEAHA.113.003393. Epub 2014 Jan 2.
 
Bai Y1, Nie S, Jiang G, Zhou Y, Zhou M, Zhao Y, Li S, Wang F, Lv Q, Huang Y, Yang Q, Li Q, Li Y, Xia Y, Liu Y, Liu J, Qian J, Li B, Wu G, Wu Y, Wang B, Cheng X, Yang Y, Ke T, Li H, Ren X, Ma X, Liao Y, Xu C, Tu X, Wang QK.
 
1From the Key Laboratory of Molecular Biophysics of the Ministry of Education, Cardio-X Institute (Y.B., G.J., Yingchao Zhou, M.Z., Yuanyuan Zhao, S.L., F.W., Q. Lu, Y.H., Q.Y., T.K., H.L., X.R., C.X., X.T., Q.K.W.), and College of Life Science and Technology and Center for Human Genome Research, Institute of Cardiology (S.N., X.C., Y. Liao), Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Cardiology, Jining Medical College Affiliated Hospital, Jining, China (Q. Li); Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin, China (Y. Li); Department of Cardiology, First Affiliated Hospital of Dalian Medical University, Dalian, China (Y.X., Y. Liu, J.L., Y.Y.); Department of Cardiology, Suizhou Central Hospital, Suizhou, China (J.Q.); Department of Cardiology, Xiangyang Central Hospital, Xiangyang, China (B.L.); Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China (G.W.); Department of Cardiology, Wuhan No. 1 Hospital, Wuhan, China (Y.W.); Research Institute of the National Population and Family Planning Commission, Beijing, China (B.W., X.M.); and Department of Molecular Cardiology, Center for Cardiovascular Genetics, Lerner Research Institute, Cleveland Clinic, OH (Q.K.W.).
 
HUM-CELL-0020 ,PriCells, Wuhan, China
 
Abstract
BACKGROUND AND PURPOSE:
ANRIL has long been considered as the strongest candidate gene at the 9p21 locus, robustly associated with stroke and coronary artery disease. However, the underlying molecular mechanism remains unknown. The present study works to elucidate such a mechanism.
METHODS:
Using expression quantitative loci analysis, we identified potential genes whose expression may be influenced by genetic variation in ANRIL. To verify the identified gene(s), knockdown and overexpression of ANRIL were evaluated in human umbilical vein endothelial cells and HepG2 cells. Ischemic stroke and coronary artery disease risk were then evaluated in the gene(s) demonstrated to be mediated by ANRIL in 3 populations of Chinese Han ancestry: 2 ischemic stroke populations consisting of the Central China cohort (903 cases and 873 controls) and the Northern China cohort (816 cases and 879 controls) and 1 coronary artery disease cohort consisting of 772 patients and 873 controls.
RESULTS:
Expression quantitative loci analysis identified CARD8 among others, with knockdown of ANRIL expression decreasing CARD8 expression and overexpression of ANRIL increasing CARD8 expression. The minor T allele of a previously identified CARD8 variant (rs2043211) was found to be significantly associated with a protective effect of ischemic stroke under the recessive model in 2 independent stroke cohorts. No significant association was found between rs2043211 and coronary artery disease.
CONCLUSIONS:
CARD8 is a downstream target gene regulated by ANRIL. Single nucleotide polymorphism rs2043211 in CARD8 is significantly associated with ischemic stroke. ANRIL may increase the risk of ischemic stroke through regulation of the CARD8 pathway.

上一篇

贺武汉大学生命科学学院应用PriCells产品/技术服务发表文章

下一篇

贺温州医科大学附属第一医院应用PriCells产品/技术服务发表文章

更多资讯

我的询价